V. Aleksiev, Daniel Markov, K. Bechev, B. Yavorov, F. Shterev
2026.4.16Folia Medica
Abstract
Introduction : Malignant pleural effusions (MPEs) are a frequent complication of cancer, causing significant morbidity and representing a major diagnostic challenge. Tumor markers in pleural fluid have been studied, but their interrelationships remain poorly understood. Aim : To investigate the correlations among commonly used tumor markers in pleural effusions and to assess their potential role in differentiating malignant from benign cases. Materials and methods : A cross-sectional case-control study was conducted on 151 Bulgarian patients with hydrothorax. The control group consisted of 72 patients with benign pleural effusions (38 inflammatory, 34 non-inflammatory), while 79 patients had malignant pleural involvement. Correlation analysis was applied to evaluate the relationships between carcinoembryonic antigen (CEA), CA19-9, CA72-4, CA125, CA15-3, and PIVKA-II. Results : Significant moderate positive correlations were found between CEA, CA19-9, CA72-4, and CA125, indicating overlapping tumor biology. CA125 also correlated with CA15-3, consistent with their role in epithelial malignancies. In contrast, PIVKA-II showed no significant correlation with other markers, suggesting limited utility in pleural malignancy diagnosis. These findings point to both redundancy and complementarity among tumor markers. Conclusions : Tumor markers in pleural fluid, particularly CEA, CA125, CA19-9, and CA72-4, may provide valuable diagnostic information when assessed together. Their interrelationships support the rational selection of marker panels to improve diagnostic accuracy for MPEs. PIVKA-II appears less informative in this setting. Understanding these correlations may enhance minimally invasive diagnostic strategies and contribute to more personalized management of pleural malignancy.
Citation format
ALEKSIEV, V., et al. Correlation patterns of CEA, CA19-9, CA72-4, CA125, CA15-3, and PIVKA-II in malignant pleural effusions: Overlap and distinction across tumor biology. Folia Medica, 2026, 68(2).